GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (STU:QTS) » Definitions » Cyclically Adjusted PB Ratio

IQVIA Holdings (STU:QTS) Cyclically Adjusted PB Ratio : 8.51 (As of May. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is IQVIA Holdings Cyclically Adjusted PB Ratio?

As of today (2024-05-20), IQVIA Holdings's current share price is €212.40. IQVIA Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €24.95. IQVIA Holdings's Cyclically Adjusted PB Ratio for today is 8.51.

The historical rank and industry rank for IQVIA Holdings's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:QTS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 7.28   Med: 10.55   Max: 16.99
Current: 8.52

During the past years, IQVIA Holdings's highest Cyclically Adjusted PB Ratio was 16.99. The lowest was 7.28. And the median was 10.55.

STU:QTS's Cyclically Adjusted PB Ratio is ranked worse than
90.98% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 2 vs STU:QTS: 8.52

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

IQVIA Holdings's adjusted book value per share data for the three months ended in Mar. 2024 was €32.033. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €24.95 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


IQVIA Holdings Cyclically Adjusted PB Ratio Historical Data

The historical data trend for IQVIA Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQVIA Holdings Cyclically Adjusted PB Ratio Chart

IQVIA Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 15.90 9.84 9.02

IQVIA Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.91 9.55 7.96 9.02 9.32

Competitive Comparison of IQVIA Holdings's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, IQVIA Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IQVIA Holdings's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's Cyclically Adjusted PB Ratio falls into.



IQVIA Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

IQVIA Holdings's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=212.40/24.95
=8.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IQVIA Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, IQVIA Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=32.033/131.7762*131.7762
=32.033

Current CPI (Mar. 2024) = 131.7762.

IQVIA Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201406 -3.599 100.560 -4.716
201409 -3.259 100.428 -4.276
201412 -4.600 99.070 -6.119
201503 -4.529 99.621 -5.991
201506 -5.098 100.684 -6.672
201509 -2.939 100.392 -3.858
201512 -4.337 99.792 -5.727
201603 -3.264 100.470 -4.281
201606 -3.443 101.688 -4.462
201609 -2.339 101.861 -3.026
201612 34.767 101.863 44.977
201703 32.221 102.862 41.278
201706 31.006 103.349 39.534
201709 25.791 104.136 32.637
201712 32.464 104.011 41.130
201803 32.003 105.290 40.054
201806 31.129 106.317 38.583
201809 30.565 106.507 37.817
201812 29.882 105.998 37.149
201903 29.687 107.251 36.476
201906 29.483 108.070 35.951
201909 28.696 108.329 34.907
201912 28.095 108.420 34.147
202003 26.259 108.902 31.775
202006 25.953 108.767 31.443
202009 25.891 109.815 31.069
202012 25.799 109.897 30.935
202103 26.099 111.754 30.775
202106 24.952 114.631 28.684
202109 25.927 115.734 29.521
202112 28.054 117.630 31.428
202203 28.391 121.301 30.843
202206 27.133 125.017 28.600
202209 29.066 125.227 30.586
202212 29.306 125.222 30.840
202303 29.868 127.348 30.907
202306 28.975 128.729 29.661
202309 29.804 129.860 30.244
202312 30.880 129.419 31.442
202403 32.033 131.776 32.033

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IQVIA Holdings  (STU:QTS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


IQVIA Holdings Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IQVIA Holdings (STU:QTS) Business Description

Traded in Other Exchanges
Address
2400 Ellis Road, Durham, NC, USA, 27703
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.